Aysel Sünnetçioğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aysel Sünnetçioğlu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Ufuk Kömüroğlu
Van Yuzuncu Yil University, Vocational School of Health Services, 65080, Van, Turkey
1 shared publication - Gulhan Bora
VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, ECZACILIK TEMEL BİLİMLERİ BÖLÜMÜ
1 shared publication - Hakan Aydın
Lokman Hekim Universitesi
1 shared publication - Hülya Günbatar
Van Yuzuncu Yil Universitesi
1 shared publication - Murat Alay
Van Yuzuncu Yil Universitesi
1 shared publication - Müslüm Buzkurt
SBÜ VAN EĞİTİM VE ARAŞTIRMA HASTANES
1 shared publication
Latest Publications
- Open Access
- 30 August 2025
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- Vol. 18 (2) , 123-130
Lipolyse Enzyms Levels in Patients with Obstructive Sleep Apnea Syndrome; Especially Perilipin-1
Introduction: Since obesity is an important risk factor in obstructive sleep apnea syndrome (OSAS), it will be important to determine the relationship between intracellular and intravascular lipolysis enzymes and OSAS. In this study we investigated the levels of lipolysis enzymes Perilipin-1 (Plin-1), adipose triglyceride lipase (ATGL), hormon sensitive lipase (HSL) and lipoprotein lipase (LPL) in patients with OSAS and the relationship between these enzymes and OSAS. Material method: 51 OSAS patients with obstructive sleep apnea syndrome and 25 volunteers diagnosed with simple snoring as a control group were included in the study. Polysomnographic evaluation, age, gender, and body mass index of each participant were recorded. Blood was taken from the participants on the same day to analyze enzymes. Results: Between the OSAS group (n:51) and the control group (n:25), age (mean: 45.3±10 vs 40.9±9.1, p value: 0.065), gender (female/male in the patient and control group, respectively: 5/46, 3/22, p value: 0.76) and BMI (min-max 23.3-40.1 vs 24-44.1, p value: 0.21, respectively) were similar. For ATGL, HSL, LPL, no significant difference was detected between the groups (median values: 65.9 vs 68.3, 7.30 vs 7.33, 484.2 vs 485.3, p values: 0.33, 0.69, 0.33, respectively). Plin-1 level was found to be significantly higher in the OSAS group (median value: 5.34 vs 4.87 ng/ml, p:0.038). It was determined that Plin-1 had a positive correlation with WASO (wake after sleep onset) and a negative correlation with total sleep time (p value: 0.003, 0.006, r value: 0.41, -0.38, respectively). In the linear regression analysis performed for the OSAS group, WASO was detected as a risk factor for Plin-1 elevation (p: 0.003, B: 0.012). Conclusion: We found that Plin-1 levels increased secondary to sleep disruptions in patients with OSAS, independent of obesity.
- 30 August 2025
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- Vol. 18 (2) , 123-130
Open AccessLipolyse Enzyms Levels in Patients with Obstructive Sleep Apnea Syndrome; Especially Perilipin-1
Introduction: Since obesity is an important risk factor in obstructive sleep apnea syndrome (OSAS), it will be important to determine the relationship between intracellular and intravascular lipolysis enzymes and OSAS. In this study we investigated the levels of lipolysis enzymes Perilipin-1 (Plin-1), adipose triglyceride lipase (ATGL), hormon sensitive lipase (HSL) and lipoprotein lipase (LPL) in patients with OSAS and the relationship between these enzymes and OSAS. Material method: 51 OSAS patients with obstructive sleep apnea syndrome and 25 volunteers diagnosed with simple snoring as a control group were included in the study. Polysomnographic evaluation, age, gender, and body mass index of each participant were recorded. Blood was taken from the participants on the same day to analyze enzymes. Results: Between the OSAS group (n:51) and the control group (n:25), age (mean: 45.3±10 vs 40.9±9.1, p value: 0.065), gender (female/male in the patient and control group, respectively: 5/46, 3/22, p value: 0.76) and BMI (min-max 23.3-40.1 vs 24-44.1, p value: 0.21, respectively) were similar. For ATGL, HSL, LPL, no significant difference was detected between the groups (median values: 65.9 vs 68.3, 7.30 vs 7.33, 484.2 vs 485.3, p values: 0.33, 0.69, 0.33, respectively). Plin-1 level was found to be significantly higher in the OSAS group (median value: 5.34 vs 4.87 ng/ml, p:0.038). It was determined that Plin-1 had a positive correlation with WASO (wake after sleep onset) and a negative correlation with total sleep time (p value: 0.003, 0.006, r value: 0.41, -0.38, respectively). In the linear regression analysis performed for the OSAS group, WASO was detected as a risk factor for Plin-1 elevation (p: 0.003, B: 0.012). Conclusion: We found that Plin-1 levels increased secondary to sleep disruptions in patients with OSAS, independent of obesity.
- Open Access
- 12 October 2022
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- p. 192-200
Göğüs Hastalıkları Servisinde Yatan Hastalardan İzole Edilen Gram Negatif Bakteri Profili ve Antibiyotik Dirençliliğinin Değerlendirilmesi: Van Ölçekli Retrospektif Çalışma
Amaç: Pnömoni, KOAH, Bronşektazi, Hışıltı (Wheezing), Astım ve Bronşit tanıları ile göğüs hastalıkları servisine başvuruda bulunan hastaların balgam kültür sonuçlarında üreyen bakteri/bakterilerin antibiyotik direnç profillerinin belirlenmesidir. Materyal ve Metot: Ocak 2021- Şubat 2022 tarihleri arasında Göğüs Hastalıkları Servisinde yatarak tedavi gören Pnömoni, KOAH, Bronşektazi, Hışıltı (Wheezing), Astım ve Bronşit tanılı olgularda çalışılan balgam kültürleri, üreyen mikroorganizmalar ve antibiyotik dirençleri retrospektif olarak tarandı. 20-87 yaş arası; yaş ortalaması 36,2 olan, 295’i (%59) erkek, 205’i (%41) kadın olmak üzere toplam 500 hasta izlendi. Kültürde üremesi olmayan hastalar çalışmaya dahil edilmedi. Bulgular: 30 hastada Acinetobacter baumannii/haemolyticus, 16 hastada Enterobacter cloacae, 97 hastada Escherichia coli, 28 hastada Gram - Bacilli 12 hastada Haemophilus influenzae, 13 hastada Klebsiella oxytoca, 42 hastada Klebsiella pneumoniae, 13 hastada Klebsiella pneumoniae ssp ozaenae, 79 hastada Klebsiella pneumoniae ssp pneumoniae, 11 hastada Klebsiella species, 20 hastada Pseudomonas aeruginosa, 78 hastada Staphylococcus aureus ve 7 hastada Streptococcus pneumoniae) bakterisi üremiştir. Balgam kültürlerinde yoğun olarak üreyen bakterilerin antibiyotik dirençliliğine bakıldığımızda; Escherichia Coli, Amikasın (%16,4), Trimetoprim+ Sulfametaksazol (%8,24), Aztreonam (%9,27), Cefazolin (%6,18), Sefaperazon/Sulbaktam (%15,46), Ceftazidim (%20,61), Ampisilin+ Sulbaktam (%10,30), Cefotaxim (%13,40), Cefoxitim (%4,12), Piperasilin+ Tazobaktam (%14,43). Acinetobacter Baumanni, Amikasın (%13,33), Trimetoprim + Sulfametaksazol (%16,66), Aztreonam (%10,00), Cefazolin (%10,00), Sefaperazon/Sulbaktam (%3,33), Ceftazidim (%13,33), Ampisilin + Sulbaktam (%6,66), Cefotaxim (%10,00), Cefoxitim (%6,66), Piperasilin + Tazobaktam (%10,00). Pseudomonas Aeruginosa, Amikasın (%20,00), Trimetoprim + Sulfametaksazol (%15,00), Aztreonam (%10,00), Cefazolin (%10,00), Sefaperazon/Sulbaktam (%5,00), Ceftazidim (%5,00), Ampisilin + Sulbaktam (%15,00), Cefotaxim (%10,00), Cefoxitim (%5,00), Piperasilin + Tazobaktam (%5,00). Klebsiella Pneumonia Ssp, Amikasın (%8,86), Trimetoprim + Sulfametaksazol (%7,59), Aztreonam (%20,25), Cefazolin (%10,12), Sefaperazon/Sulbaktam (%5,06), Ceftazidim (%3,79), Ampisilin + Sulbaktam (%16,45), Cefotaxim (%11,39), Cefoxitim (%2,53), Piperasilin + Tazobaktam (%13,92). Sonuç: Pnömoni, KOAH, Bronşektazi, Wheezing, Astım ve Bronşit tanılı, mikroorganizma kökenli etkilenimi olan hastalarda izole edilen bakteriler ve bu bakterilere karşı duyarlılık-dirençlilik verilerine göre ampirik tedavi başlanması önemlidir.
- 12 October 2022
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- p. 192-200
Open AccessGöğüs Hastalıkları Servisinde Yatan Hastalardan İzole Edilen Gram Negatif Bakteri Profili ve Antibiyotik Dirençliliğinin Değerlendirilmesi: Van Ölçekli Retrospektif Çalışma
Amaç: Pnömoni, KOAH, Bronşektazi, Hışıltı (Wheezing), Astım ve Bronşit tanıları ile göğüs hastalıkları servisine başvuruda bulunan hastaların balgam kültür sonuçlarında üreyen bakteri/bakterilerin antibiyotik direnç profillerinin belirlenmesidir. Materyal ve Metot: Ocak 2021- Şubat 2022 tarihleri arasında Göğüs Hastalıkları Servisinde yatarak tedavi gören Pnömoni, KOAH, Bronşektazi, Hışıltı (Wheezing), Astım ve Bronşit tanılı olgularda çalışılan balgam kültürleri, üreyen mikroorganizmalar ve antibiyotik dirençleri retrospektif olarak tarandı. 20-87 yaş arası; yaş ortalaması 36,2 olan, 295’i (%59) erkek, 205’i (%41) kadın olmak üzere toplam 500 hasta izlendi. Kültürde üremesi olmayan hastalar çalışmaya dahil edilmedi. Bulgular: 30 hastada Acinetobacter baumannii/haemolyticus, 16 hastada Enterobacter cloacae, 97 hastada Escherichia coli, 28 hastada Gram - Bacilli 12 hastada Haemophilus influenzae, 13 hastada Klebsiella oxytoca, 42 hastada Klebsiella pneumoniae, 13 hastada Klebsiella pneumoniae ssp ozaenae, 79 hastada Klebsiella pneumoniae ssp pneumoniae, 11 hastada Klebsiella species, 20 hastada Pseudomonas aeruginosa, 78 hastada Staphylococcus aureus ve 7 hastada Streptococcus pneumoniae) bakterisi üremiştir. Balgam kültürlerinde yoğun olarak üreyen bakterilerin antibiyotik dirençliliğine bakıldığımızda; Escherichia Coli, Amikasın (%16,4), Trimetoprim+ Sulfametaksazol (%8,24), Aztreonam (%9,27), Cefazolin (%6,18), Sefaperazon/Sulbaktam (%15,46), Ceftazidim (%20,61), Ampisilin+ Sulbaktam (%10,30), Cefotaxim (%13,40), Cefoxitim (%4,12), Piperasilin+ Tazobaktam (%14,43). Acinetobacter Baumanni, Amikasın (%13,33), Trimetoprim + Sulfametaksazol (%16,66), Aztreonam (%10,00), Cefazolin (%10,00), Sefaperazon/Sulbaktam (%3,33), Ceftazidim (%13,33), Ampisilin + Sulbaktam (%6,66), Cefotaxim (%10,00), Cefoxitim (%6,66), Piperasilin + Tazobaktam (%10,00). Pseudomonas Aeruginosa, Amikasın (%20,00), Trimetoprim + Sulfametaksazol (%15,00), Aztreonam (%10,00), Cefazolin (%10,00), Sefaperazon/Sulbaktam (%5,00), Ceftazidim (%5,00), Ampisilin + Sulbaktam (%15,00), Cefotaxim (%10,00), Cefoxitim (%5,00), Piperasilin + Tazobaktam (%5,00). Klebsiella Pneumonia Ssp, Amikasın (%8,86), Trimetoprim + Sulfametaksazol (%7,59), Aztreonam (%20,25), Cefazolin (%10,12), Sefaperazon/Sulbaktam (%5,06), Ceftazidim (%3,79), Ampisilin + Sulbaktam (%16,45), Cefotaxim (%11,39), Cefoxitim (%2,53), Piperasilin + Tazobaktam (%13,92). Sonuç: Pnömoni, KOAH, Bronşektazi, Wheezing, Astım ve Bronşit tanılı, mikroorganizma kökenli etkilenimi olan hastalarda izole edilen bakteriler ve bu bakterilere karşı duyarlılık-dirençlilik verilerine göre ampirik tedavi başlanması önemlidir.